0.10
+0.003(+3.17%)
Currency In USD
Address
909 Davis Street
Evanston, IL 60201
United States of America
Phone
847 871 0377
Website
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
June 21, 2018
| Name | Title | Pay | Year Born |
| Mr. Ashish Khanna | Chief Financial Officer & Chief Bus. Officer | 603,758 | 1976 |
| Dr. Andrew D. Kidd B.M. B.Ch., M.D. | Interim Principal Executive Officer, Principal Financial Officer & Principal Accounting Officer | 736,600 | 1976 |
| Dr. Norbert G. Riedel | Executive Chairman | 851,447 | 1958 |
| Ms. Molly Dir | Vice President of Human Resources | 0 | N/A |
| Mr. Patrick Flavin | Senior Manager of Corporate Development & Investor Relations | 0 | N/A |
| Dr. Kathryn King Ph.D. | Senior Vice President of Clinical & CMC Operations | 0 | N/A |
| Mr. Tim Noffke | Vice President of Program Management & Chief of Staff | 0 | N/A |
| Dr. Harald Murck M.D., Ph.D. | Vice President of Clinical & Medical Affairs | 0 | N/A |
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.